| __timestamp | Grifols, S.A. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 17986000 |
| Thursday, January 1, 2015 | 736435000 | 32480000 |
| Friday, January 1, 2016 | 775266000 | 68081000 |
| Sunday, January 1, 2017 | 860348000 | 169906000 |
| Monday, January 1, 2018 | 814775000 | 248932000 |
| Tuesday, January 1, 2019 | 942821000 | 354100000 |
| Wednesday, January 1, 2020 | 985616000 | 433300000 |
| Friday, January 1, 2021 | 1061508000 | 583300000 |
| Saturday, January 1, 2022 | 1190423000 | 752700000 |
| Sunday, January 1, 2023 | 1254234000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Data in motion
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Over the past decade, from 2014 to 2023, Neurocrine Biosciences, Inc. and Grifols, S.A. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Grifols, S.A., a global healthcare company, has seen its SG&A costs rise by approximately 90%, reflecting its expansive growth and operational scaling. In contrast, Neurocrine Biosciences, Inc., a biopharmaceutical company focused on neurological and endocrine-related disorders, has experienced a staggering increase of nearly 4,800% in SG&A expenses, indicative of its aggressive market penetration and strategic investments. This financial narrative not only highlights the contrasting business strategies but also underscores the broader trends in the pharmaceutical sector, where innovation and expansion drive financial commitments.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.